Cell Therapeutics, Inc.

Patent coverage granted extending exclusive license of Xyotax in Japan to 2018

Published in Health Business Week, November 18th, 2005

Cell Therapeutics, Inc. (CTI) announced that it has received notification from the Japanese patent office that patent coverage extending to Xyotax (paclitaxel poliglumex) is allowable in Japan. CTI has an exclusive license to this Japanese patent property.

The patent, when issued, will provide patent protection for Xyotax in Japan until 2018. In addition to this licensed patent property in Japan, CTI has licensed issued patents in the United States and allowed coverage in Europe that encompass Xyotax.

Currently, CTI plans to submit a new drug application (NDA) and seek approval for Xyotax as first-line monotherapy for women with advanced non-small...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2005-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry